Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company completing patient enrollment in its SkinJect clinical trial. The company has now enrolled 90 patients across nine sites in the United States as part of its clinical development program for Skinject, a novel, noninvasive treatment for non-melanoma skin diseases, specifically basal cell carcinoma. Proactive: All right, welcome back inside our Proactive newsroom. And joining me now is Dr Raza Bokhari. He is the CEO of Med ...